By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Synageva BioPharma 

Corporate Offices
128 Spring Street, Suite 520
Lexington  Massachusetts  02421  U.S.A.
Phone: 781-890-1111 Fax: 781-890-1114


SEARCH JOBS

Synageva BioPharma is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic products for patients with life-threatening rare diseases and unmet medical need. Our lead program, SBC-102, an enzyme replacement therapy for LAL Deficiency, is currently being evaluated in global Phase I/II clinical trials. SBC-102 has been granted orphan designations by the U.S. Food and Drug Administration (“FDA”) and the European Medicines Agency and fast track designation by the FDA. Synageva has several protein therapeutics focused on life threatening conditions in its pipeline. The Company has assembled a team with a proven record of bringing orphan therapies to patients.


Key Statistics


Email: info@synageva.com
Ownership: Public

Web Site: Synageva BioPharma
Employees:
Symbol: GEVA
 









Company News
Synageva BioPharma (GEVA) To Present At The Morgan Stanley (MST) Global Healthcare Conference 9/2/2014 1:27:43 PM
Synageva BioPharma (GEVA) To Present At The Baird 2014 Healthcare Conference 8/26/2014 9:32:42 AM
Synageva BioPharma (GEVA) To Present At Upcoming Investor Conferences 8/4/2014 6:36:04 AM
Synageva BioPharma (GEVA) Reports Second Quarter 2014 Financial Results 7/31/2014 8:28:22 AM
Synageva BioPharma (GEVA) Details Positive Phase 3 Data Of Sebelipase Alfa 7/1/2014 7:22:04 AM
Synageva BioPharma (GEVA) Highlights Data Presentations And Satellite Symposium At The European Atherosclerosis Society Congress 6/3/2014 6:38:36 AM
Synageva BioPharma (GEVA) To Present At The Jefferies and Co. And Goldman, Sachs & Co. Healthcare Conferences 5/28/2014 6:45:45 AM
Synageva BioPharma (GEVA) Announces Satellite Symposium At The National Lipid Association 5/2/2014 9:40:39 AM
Synageva BioPharma (GEVA) Reports First Quarter 2014 Financial Results 5/1/2014 2:44:54 PM
Synageva BioPharma (GEVA) Release: LAL Deficiency Disease Review Published In Atherosclerosis 4/21/2014 9:37:22 AM
12345678910
//-->